Objective-Drug-eluting stents eluting canonical mTOR (mammalian target of rapamycin) inhibitors are widely used to treat coronary artery disease but accelerate the development of atherosclerosis within the stent (neoatherosclerosis)-a leading cause of late stent failure. We recently showed that canonical mTOR inhibitors bind FKBP12.6 (12.6-kDa FK506-binding protein 12), displace it from calcium release channels, resulting in activation of PKCα (protein kinase Cα) and dissociation of p-120-catenin (p120) from VE-CAD (vascular endothelial cadherin; promoting endothelial barrier dysfunction [EBD]). However, the relevance of these findings to drug-eluting stents remains unknown. Newer generation direct mTOR kinase inhibitors do not bind FKBP12.6 and offer the potential of improving endothelial barrier function while maintaining antirestenotic efficacy, but their actual effects are unknown. We examined the effects of 2 different pharmacological targeting strategies-canonical mTOR inhibitor everolimus and mTOR kinase inhibitors Torin-2-on EBD after stenting. Approach and Results-Using the rabbit model of stenting and a combination of Evans blue dye, confocal and scanning electron microscopy studies, everolimus-eluting stents resulted in long-term EBD compared with bare metal stents. EBD was mitigated by using stents that eluted mTOR kinase inhibitors (Torin-2-eluting stent). At 60 days after stent placement, everolimus-eluting stents demonstrated large areas of Evans blue dye staining and evidence of p120 VE-CAD dissociation consistent with EBD. These findings were absent in bare metal stents and significantly attenuated in Torin-2-eluting stent. As proof of concept of the role of EBD in neoatherosclerosis, 100 days after stenting, animals were fed an enriched cholesterol diet for an additional 30 days. Everolimus-eluting stents demonstrated significantly more macrophage infiltration (consistent with neoatherosclerosis) compared with both bare metal stents and Torin-2-eluting stent. Conclusions-Our results pinpoint interactions between FKBP12.6 and canonical mTOR inhibitors as a major cause of vascular permeability and neoatherosclerosis, which can be overcome by using mTOR kinase inhibitors. Our study suggests further refinement of molecular targeting of the mTOR complex may be a promising strategy (Graphic Abstract). Visual Overview-An online visual overview is available for this article.
ndothelial cells (ECs) form a barrier between the lumen and the vessel wall. Endothelial barrier dysfunction (EBD) is believed to be the inciting event in atherosclerosis because it allows lipoproteins to infiltrate the subendothelium. 1 Drug-eluting stents (DESs), which elute canonical mTOR (mammalian target of rapamycin) inhibitors, such as sirolimus or everolimus (EVL), are used to treat coronary artery disease because they prevent restenosis compared with bare metal stents (BMS). Inhibition of mTOR and its downstream effectors eukaryotic initiation factor 4E-binding protein-1, S6 kinase (p70S6K [ribosomal protein S6 kinase β-1]), and Akt (protein kinase B) are the primary mechanisms by which DESs reduce neointimal formation. 2 However, their use is associated with the rapid development of neoatherosclerosis, which may lead to in-stent thrombosis from plaque rupture and is the second leading cause of late stent failure. 3 The development of neoatherosclerosis is accelerated in DES compared with BMS, developing during a period of months to few years. 4 In comparison, native vessel atherosclerosis develops for decades.
Although previous data suggest an important role for endothelial permeability in the development of native vessel atherosclerosis, its role in neoatherosclerosis remains unknown. ECs control the entry of leukocytes and lipoproteins into the subendothelial space through endothelial adherens junctions. 5 VE-CAD (vascular endothelial cadherin) mediates the integrity of EC cell-cell contacts via Ca 2+ -dependent interactions. VE-CAD is stabilized by a complex of proteins, including β-catenin and p120, which are anchored to the actin fibers of the endothelial cytoskeleton. 6 Lack of catenin association destabilizes cadherin-mediated cell adhesion. 7 We recently identified a mechanism by which sirolimus promotes endothelial permeability, independent of the mTOR signaling pathway. Sirolimus (and analogs, such as EVLeluting stents [EES] ) inhibit mTOR through binding of the FKBP12 (FK506-binding protein 12)-a stabilizer of RyR2 (ryanodine receptor 2) intracellular Ca 2+ release channels. By displacing FKBP12.6 (12.6-kDa FKBP12; vascular-specific isoform), sirolimus leads to Ca 2+ -dependent activation of PKCα (protein kinase Cα), p120 phosphorylation, and p120-VE-CAD dissociation, impairing endothelial barrier function (EBF). 8 These results suggest impairment of EBF in DES and that strategies to inhibit mTOR directly without FKBP12.6 may improve EBF and eventually neoatherosclerosis, while maintaining antirestenotic efficacy.
Using a model of arterial stenting, we examined the role of FKBP12. 6 in increasing endothelial permeability and tested a strategy to overcome it. We compared EBF assessed by Evans blue dye, confocal microscopy for p120/VE-CAD colocalization, and scanning electron microscopy (SEM) for endothelial surface morphology in BMS, EES, and Torin-2-eluting stents (TESs)-a newer generation selective ATP-competitive direct mTOR kinase inhibitor that does not bind FKBP12. 6. 9 To examine the association between impaired EBF and neoatherosclerosis, we performed a proof-of-concept study, with cholesterol feeding of animals and examined the extent of macrophage infiltration.
Materials and Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
In Vitro Experiments
Western blotting and transendothelial electrical resistance (TEER) measurements were performed on human aortic ECs (HAECs; Cell Applications, San Diego, CA), which were maintained in Human MesoEndo Endothelial Cell Media (Cell Applications catalog No. 212-500) and passages between 3 and 6 were used. For all experiments, HAECs were washed twice with PBS solution after each application of treatment for the indicated times. HAECs were treated with either EVL (500 nmol/L, catalog No. S1120; Selleckchem, Houston, TX) or Torin-2 (100 nmol/L, catalog No. 4248; Tocris, Bristol, United Kingdom) dissolved in Dimethyl sulfoxide (DMSO). Control cells received DMSO. The dose of EVL was chosen to approximate average tissue levels during the course of 60 to 90 days after stenting (drug levels at 90 days, 0.38 ng/mg of tissue) and was based on preclinical data from the rabbit iliac model. 10 Dosing of Torin-2 was based on a half maximal inhibitory concentration value of 0.25 nmol/L for mTOR inhibition compared with 1.6 to 2.4 nmol/L for EVL. 11, 12 The drugs were applied together with full endothelial growth media at 37°C with 5% carbon dioxide. Ryanodine (50 µmol/L, catalog No. ab120083; Abcam, Cambridge, United Kingdom) is an alkaloid and stabilizer of the ryanodine release channel (RyR). 13 Cells were pretreated with ryanodine for 60 minutes before EVL treatment. The relative effects of various signaling molecules in the mTOR pathway were evaluated using siRNA-mediated knockdown of FKBP12.6, AKT, and p70S6K, in HAECs. HAECs were plated at 50% confluence for transfection on the next day. siRNA transfection and knockdown efficiency were validated previously.
8,14

Test Devices and Grouping
Three different devices were implanted. The test device was a thin-strut durable polymer metallic EES (Promus Element; Boston Scientific, Marlborough, MA), 3.0×16 mm, platinum-chromium platform, 81 μm strut thickness, consisting of an inner layer of poly n-butyl methacrylate polymer surrounded by poly (vinylidene fluoride-co-hexafluoropropylene), which is comprised of vinylidene fluoride and hexafluoropropylene monomers as the drug matrix layer containing 100 µg/cm 2 of EVL. It was compared with a thinstrut BMS of the same backbone (OMEGA; Boston Scientific, Marlborough, MA), 3.0×12 mm, n=20 (platinum-chromium platform, 81 μm strut thickness) as control. A custom-made TES, 3.0×16 mm (platinum-chromium platform, 81 μm strut thickness using OMEGA backbone), was manufactured by Boston Scientific by the same techniques used for the EES (poly n-butyl methacrylate primer layer with poly [vinylidene fluoride-co-hexafluoropropylene] plus 100 µg/cm 2 Torin-2 [Selleck Chemicals, Houston, TX] in the external layer). Using this polymer in combination with drug has been shown to release the majority of drug within 3 months.
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Animal Model
The study protocol was approved by the Institutional Animal Care and Use Committee of the MedStar Health Research Institute and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health. A total of 35 healthy male New Zealand white rabbits (5-6 months; Millbrook Laboratories, Amherst, MA) were included in the study. A model of iliofemoral stent implantation was used as described previously, to study endothelialization and inflammatory reaction after stenting. 10 Stents were assigned to animals using a design such that each animal received stents of 2 different types ( Table I in the online-only Data Supplement). Standard follow-up angiography using contrast media was performed to confirm stent patency before explantation. Evans blue permeability, VE-CAD/p120 colocalization, and endothelialization were assessed in 1 cohort, 60 days after implantation (17 animals, 34 stents, 13 BMS, 12 EES, and 9 TES). Two BMS and 3 TES were excluded because of evidence of damage to endothelium, which occurred during harvest. S6K and Akt inhibition, as well as neointimal formation, was assessed using Western blotting in another cohort (5 animals, 10 stents, 3 BMS, 4 EES, and 3 TES) 28 days after implantation. Stents were cut longitudinally, and one-half was used for histological measurement of neointima formation and strut coverage by plastic embedding and sectioning. An additional 4 animals (3 BMS, 3 EES, and 2 TES) were used to analyze endothelial mTOR inhibition. To understand the differential in-stent atherosclerotic reaction, another assessment was performed at 130 days after feeding with a cholesterol-enriched diet (0.15% wt/wt; Bio Serv, Flemington, NJ) for 30 days from day 100 till euthanization (6 animals, n=4 stents per group). One TES was excluded from analysis because of evidence of damage to endothelium, which occurred during harvest.
Evans Blue Staining Analysis
Evans blue dye is widely used to study blood vessel and cellular membrane permeability because it is nontoxic, it can be administered as an intravital dye, and it binds to serum albumin-using this as its transporter molecule. The Evans blue dye-albumin conjugate can be identified macroscopically by the striking blue color within tissue. Evans blue was injected intravenously, 1 hour before euthanization to allow circulation. After fixation, stents were bisected longitudinally. Images of the luminal side were acquired with a mounted camera (Canon EOS Rebel XSi; Lake Success, NY). Evans blue quantification was done on HALO software, version 2.0 (Indica Laboratories, Corrales, NM) using area quantification module. Measurements are presented as percentage of the total measured area.
Confocal Microscopy of Stents
The halved stents were treated with Triton-X 0.1% and then incubated with primary antibodies (VE-CAD dilution, DAPI was used as a nuclear counterstain (Invitrogen). The specimens were mounted en face on glass slides, and images were acquired using 10× 0.45NA objective on a Carl Zeiss LSM 880 (Oberkochen, Germany) with Zen software (black edition), v2.3 (Carl Zeiss). Three-dimensional projections were rendered using maximum intensity projection processing of Z-stacked images. Areas were measured using calibrated Zen software. Quantification of the RAM11-positive area was done using Zen Blue, v2.3, with a fixed threshold. Highresolution images were taken with a 20× 1.0NA using super resolution AiryScan module. For a negative control, secondary antibodies were used alone without primary antibody incubation. Cell shape index of a ratio of X and Y dimensions of ECs was assessed from 8 randomly selected cells from 20× images of the proximal, middle, and distal areas of the stent.
Scanning Electron Microscopy
After confocal microscopic analysis, the stented artery halves designated for SEM were rinsed in 0.1 mol/L sodium phosphate buffer and postfixed in 1% osmium tetroxide for ≈30 minutes. The samples were then dehydrated in a graded series of ethanol, critically point-dried, and sputter-coated with gold. The specimens were visualized using a Hitachi Model S3400N or S3600N scanning electron microscope. Low-power photographs (×15 magnification) were acquired of the luminal surface to estimate the degree of neointimal incorporation of the implant. From these images, strut coverage rates were semiquantified by visual estimation from the proximal to distal end. High-power SEM images (400-600×) from randomly selected areas were taken (3 areas from 3 stents at each time point). From these images, the numbers of surface monocytes (per mm 2 ) were counted. Corresponding areas from confocal microscopy were also identified, and the numbers of surface monocytes were stratified by corresponding high and low VE-CAD/p120 colocalization. Monocyte count is based on the extrapolation using the relative high and low colocalization ratios (Figure V in the online-only Data Supplement).
Statistical Analysis
Continuous variables with normal distribution are expressed as mean±SE unless stated otherwise. The Shapiro-Wilk test was used to check for normality of data distribution. Generalized estimating equations method with linear or Gamma regression model was used to compare the data from the stents in SPSS software, version 22 (IBM, Chicago, IL). Correlation between VE-CAD/p120 colocalization and Evans blue staining was done with nonparametric Spearman correlation because of non-normal distribution (P calculated is 2 tailed). In vitro cell culture comparisons of variables with normal distribution were tested by ANOVA. Data graphs were prepared using GraphPad Prism, version 7.02, for windows. P value of <0.05 was considered statistically significant.
Results mTOR Inhibition by EVL Impairs EBF via Ca
2+ -Dependent Activation of PKCα, Whereas Torin-2 Does Not
We compared the relative effects of 2 different mTOR inhibitors: one which requires FKBP12.6 to inhibit mTOR (EVL) versus a newer generation direct mTOR inhibitor Torin-2 which does not.
11 A dose-response curve comparing inhibition of mTOR targets Akt and p70S6K (S6K) in HAECs treated overnight with EVL or Torin-2 was conducted. Western blotting for phosphorylated Akt and S6K revealed inhibition of S6K by both EVL and Torin-2 at ≥10-nmol/L doses with higher doses of both agents being required to inhibit phosphorylated Akt ( Figure I in the online-only Data Supplement). Only higher doses of EVL increased phosphorylated PKCα, whereas Torin-2 had no effect ( Figure I in the online-only Data Supplement). Endothelial permeability was measured using TEER. Higher doses of EVL (100 and 500 nmol/L) decreased TEER significantly, whereas only 500 nmol/L of Torin-2 demonstrated a significant decrease in TEER, which was not to the same degree as EVL ( Figure II in the online-only Data Supplement). To compare the effect of the 2 different agents in vitro on various aspects of EC behavior, we used 500 nmol/L EVL-a dose chosen to approximate average tissue levels during the course of 60 to 90 days (drug levels at 90 days, 0.38 ng/mg of tissue) using preclinical data from the rabbit iliac model. 11 For Torin-2, a dose of 100 nmol/L was used, which was based on a half maximal inhibitory concentration value of 0.25 nmol/L for mTOR inhibition compared with 1.6 to 2.4 nmol/L for EVL. 10 The addition of EVL (500 nmol/L) to a cultured confluent HAECs caused a significant decrease in TEER relative to control culture media (ie, DMSO), indicating impaired EBF ( Figure 1A) . Pretreatment with ryanodine (50 μM) was used to stabilize RyR2 Ca 2+ release channels and decreased significantly the effect of EVL on TEER ( Figure 1A) , suggesting the effect of EVL on EBD is dependent on RyR2 activation. Treatment with 100 nM Torin-2 caused significantly less reduction in TEER, compared with 500 nM EVL but still more than DMSO ( Figure 1B) . Knockdown of FKBP12.6 in Torin-2-treated HAECs by siRNA caused an additional significant decrease in TEER compared with Torin-2-treated cells transfected with scrambled siRNA ( Figure 1C) . To assess the relative contribution of downstream targets of mTOR versus FKBP12.6, HAECs were transfected with siRNA directed against Akt, p70S6K, and FKBP12.6 and TEER measured 24 hours later. All groups differed significantly from scrambled siRNA-treated cells, with FKBP12.6 siRNA having the greatest impact on TEER ( Figure 1D) . The relative inhibitory effect of EVL (500 nmol/L) versus Torin-2 (n=4 per treatment) . B, Normalized TEER analysis of confluent HAECs treated with EVL (500 nM), Torin-2 (100 nM), or control (DMSO; n=4 per treatment). C, Normalized TEER measurements of HAECs treated with Torin-2 24 h after transfection with FKBP12.6 siRNA (black), scrambled siRNA (red), or DMSO treatment transfected with scrambled siRNA (n=4 per treatment). D, Absolute steady-state TEER measurements of HAECs transfected with FKBP12.6 siRNA, p70S6K siRNA, AKT siRNA, or scrambled siRNA 24 h after transfection (n=3 per treatment). E and F, Immunoblotting (IB) of HAECs treated with DMSO, EVL (500 nM), or Torin-2 (100 nM) for phosphorylated p70s6k (p-p70S6K) and phosphorylated Akt (p-AKT), and the total unphosphorylated form of each with corresponding densitometry shown below (n=3 per group). G, IB for phospho-PKCα (protein kinase Cα) and β-actin in HAECs treated as in (E and F; results were normalized to β-actin). H, Normalized ratiometric Ca 2+ measurement of HAECs using Fura Red and Fluo-3 blue treatment with EVL (red) or Torin-2 (blue, n=3; P value is from Mann-Whitney U test). I, p120 was immunoprecipitated from HAEC lysates 2 h after DMSO, EVL (500 nM), or Torin-2 (100 nM) treatment. Precipitates were IB for VE-CAD (vascular endothelial cadherin). Total cell lysates were also IB for the respective antibodies and representative examples shown. Densitometry quantification is shown on right for the association of p120 with VE-CAD (n=3). J, Immunofluorescent imaging of HAECs using VE-CAD (red) and p120 (green) antibodies was performed 12 h after DMSO (control), Torin-2 (100 nM), or EVL (500 nM) treatments. White arrows denote interendothelial gaps. White bar indicates 50 µm. K and L, IB of neointimal tissue from rabbit iliac arteries stented with bare metal stent (BMS), Torin-2-eluting stent (TES), or EVL-eluting stent (EES) at 28 d for the indicated proteins with densitometry shown below (n=3 BMS, 4 EES, and 3 TES per group). Note the significant reductions in downstream mTOR effectors p-p70s6k and p-Akt relative to BMS-treated vessels. M, Representative histological sections (stained with Movat Pentachrome) from BMS, TES, and EES in stented rabbit iliac arteries at 28 d. P values were calculated by ANOVA test parametric analysis with Dunn multiple comparisons post hoc testing. NS indicates nonsignificant.
(100 nmol/L) on mTOR was confirmed by Western blotting in HAECs. Both drugs showed significantly less phosphorylated p70S6K and phosphorylated Akt compared with DMSO-treated cells ( Figure 1E and 1F) . We next confirmed the effect of EVL versus Torin-2 on phosphorylated PKCα (previously shown by us to be the upstream effector of EBD after sirolimus treatment) using Western blotting. 8 In cultured HAECs, EVL but not Torin-2 resulted in significant increased phosphorylated PKCα versus control ( Figure 1G) , consistent with dose curve data shown in Figure I in the online-only Data Supplement. Consistent with this, we observed a significant increase in intracellular free Ca 2+ concentration as early as 10 minutes after EVL treatment of HAECs, which was not seen after Torin-2 treatment ( Figure 1H ). The interaction of p120 with VE-CAD in EVL versus Torin-2-treated HAECs was examined using immunoprecipitation for p120 and was significantly decreased (relative to Torin-2-treated cells) after 2 hours of drug exposure ( Figure 1I ). To confirm the effect of EVL versus Torin-2 on VE-CAD junction formation, we examined the interaction of p120 and VE-CAD by immunostaining in HAECs treated with DMSO, Torin-2, or EVL overnight ( Figure 1J ). EVL treatment increased VE-CAD mobilization from the membrane into the cytosol (relative to DMSO) with evidence of intracellular deposits and interendothelial gaps, whereas in DMSO-treated cells, there was colocalization of p120 and VE-CAD (yellow border) with no evidence of gap formation. In Torin-2-treated cells, there was evidence of colocalization of p120 and VE-CAD at cell borders with minimal interendothelial gap formation.
To understand the effects of BMS, EES, and TES on vascular endothelium, we constructed stents made of the same platinum-chromium backbone (OMEGA; Boston Scientific, Marlborough, MA). To produce DES, commercially available Promus stents containing 100 µg/cm 2 of EVL were used. For TES, stents with similar backbone and polymer structure were constructed containing 100 µg/cm 2 Torin-2. BMS, EES, or TES was implanted in rabbit iliac arteries (Table I in 
Vascular Permeability Is Enhanced After EES but Not After BMS or TES and Correlates With p120 VE-CAD Dissociation
We next examined permeability in regenerated endothelium over BMS, EES, and TES implanted for 60 days-a time point by which we estimated all stents would show complete endothelial coverage. Animals were randomized to receive BMS, EES, or TES (Figure 2A ). All animals were subjected to Evans blue dye perfusion at the time of euthanization; the stented arteries were analyzed by en face confocal immunofluorescence for VE-CAD and p120 and high-power SEM to examine stents for endothelial coverage. The Evans blue perfusion results showed little to small areas of endothelium staining with Evans blue dye in BMS and TES. In contrast, large areas of permeability were observed in EES (BMS, 8.3±8.7%; TES, 24.5±19%; EES, 70.7±15.7%; Figure 2B through 2D and Figure 2V ). In these highly permeable areas, p120 was located at cell borders by confocal immunofluorescence, whereas VE-CAD was localized to the cytoplasmic portion of the cells ( Figure 2D through 2F, 2I, 2L, 2R, and 2T) . In Evans blue-negative areas, there was complete colocalization of p120 and VE-CAD at cell borders throughout the stent best seen in BMS and TES ( Figure 2G, 2H, 2J, 2K , 2P, 2Q, and 2U; Movies I through III online-only Data Supplement). Overall negative correlation between Evans blue-positive dye staining area and the amount of VE-CAD/p120 colocalization per stent was calculated by Pearson correlation ( Figure 2W ). In cells with p120/VE-CAD colocalization, we quantified the shape of the ECs according to stent type. The ratio of length (x axis) over width (y axis) of each cell was measured in en face confocal images as a cell shape index. 15 The results showed significantly lower cell shape index in TES and EES, compared with BMS ( Figure 2X ). Cobblestone shape predominated in EES, whereas in BMS, spindle-shaped cells were primarily seen. In TES, the shape was in between. Further examination in matched high-power SEM and en face confocal imaging of areas with poor versus high colocalization of p120 and VE-CAD showed the former areas were also associated with adherent platelets and leukocytes ( Figure 2L , 2O, and 2R, black arrows: adherent leukocytes), whereas the latter areas were not. Overall, EES showed more surface area monocyte adherence than TES and BMS ( Figure V in the online-only Data Supplement).
Proof-of-Concept Neoatherosclerotic Change (Macrophage) Is Greater in EES Relative to BMS and TES
To understand the relevance of EBD in the development of neoatherosclerosis within DES, a proof-of-concept study was performed in 6 rabbits implanted with BMS, TES, or EES (n=4 stents per group) and fed a normal chow diet until 100 days after stenting at which point the diet was switched to an enriched cholesterol diet (0.15% wt/wt). The diet was continued until euthanization at 130 days ( Figure VIA C, and D) . Note how in (G, J, and M and H, K, and N) endothelial covering is smooth by SEM with complete colocalization of VE-CAD and p120 at cell borders although cell shape appears different between BMS and TES (best seen on confocal images J, K, P, Q). I, L, O, and R, images show areas lacking in colocalization of p120 and VE-CAD (I) by confocal show adherent platelet and leukocyte aggregates as seen in progressively higher power SEM images (outlined in red). S and T, (S) shows a higher power image of area with colocalization of p120 and VE-CAD, whereas (T) shows area with lack of colocalization with VE-CAD appearing within the cell cytoplasm but not at the borders (red, see arrows). U-W, Comparative data are shown for p120/VE-CAD colocalization percentage area (mean±SE) in (U) and Evans blue dye staining percent area (mean±SE) in (V), respectively, according to stent type. P values were calculated by generalized estimating equations (GEE) method with linear regression model. W, Overall, there was excellent negative correlation between Evans blue-positive staining per stent and the amount of VE-CAD/p120 colocalization per stent by nonparametric Spearman correlation. X, Average ratio of length (x axis) over width (y axis) according to stent type (mean±SE). Note how cells in BMS are spindle shaped with larger X/Y ratio while those in the EES have equal X and Y dimension while TES showed a configuration in between these two. P values were calculated by GEE method with linear regression model. EB indicates Evans blue; NS, nonsignificant; and PKCα, protein kinase Cα. 
Discussion
DES are widely used for the treatment of focal obstructive coronary artery disease, but here, we show their use is complicated by an increase in endothelial permeability, which may be responsible for the development of neoatherosclerosis within the stents. Although the mechanisms underlying neoatherosclerosis have not been elucidated, ECs provide a primary defense against atherosclerosis development and thus are an obvious area of focus. Here, we reveal that EBD is likely an important factor in the development of neoatherosclerosis and that seems to be a direct result of off-target effects of current generation mTOR inhibitors. EES showed greater permeability versus BMS and TES, and in a proof-of-concept model of neoatherosclerosis, we show greater macrophage infiltration in cholesterol-fed animals receiving EES. Our data also suggest using a stent that elutes a newer generation selective ATP-competitive inhibitor of mTOR, which does not bind FKBP12.6 ( Figure VIII in the online-only Data Supplement), may be a better option for future DES because it avoids unwanted effects on permeability caused, in part, by FKBP12.6 displacement. Collectively, our findings suggest clinical studies using stents that elute newgeneration direct mTOR inhibitors, such as TES, may successfully decrease the development of EBD, and this may result in improved outcomes in patients requiring revascularization.
Direct mTOR inhibitors are currently under evaluation for use in humans almost exclusively in oncology, where targeting the mTOR kinase is thought to result in more potent response. 16 Concerns exist about resistance to mTOR kinase inhibitors via feedback phosphoinositide 3-kinase activation. The potent mTORC1 (mammalian target of rapamycin complex 1) inhibition is thought to promote feedback activation of phosphoinositide 3-kinase-and pyruvate dehydrogenase kinase 1-driven phosphorylation of Akt at T308. We examined only the ability of Torin-2 to inhibit phosphorylation of Akt at S473 and found complete inhibition at the dose tested. Incomplete inhibition of Akt phosphorylation at T308 remains a theoretical concern, given the roles both S6K and Akt play in smooth muscle cell proliferation and migration. 14 There are also important limitations to this study. Although the animal models currently used are limited by their ability to replicate human conditions, results with the rabbit model have generally been representative of human responses, albeit with a different time course of healing. It is likely the time course of EBD seen in our animal experiments is even longer in humans. Pathology data indicate that the incidence of neoatherosclerosis progressively increases with time with nearly one-half of all DES showing the presence of neoatherosclerosis by 2 years. 4 Moreover, the proof-of-concept rabbit model of neoatherosclerosis used here did not take into account the effect of the healing process because the cholesterol diet was not given until 90 days after stenting. Last, we did not directly measure Torin-2 release from the stent although we think that the drug release and tissue drug levels would be similar for TES and EES given the drug load and polymer are identical. Although mTOR inhibition was shown to be similar by TES and EES in neointimal cells and endothelium by immunoblotting, there still remains the possibility of different degrees of endothelial mTOR inhibition by these 2 agents. We cannot completely rule out that differential suppression of mTOR by EES versus TES was the cause of differences in EBF seen. Similarly, we acknowledge that there was greater neointimal formation in TES versus EES, which illustrates the reciprocal relationship between healing and neointimal suppression. Additional experimental research would be needed before pursuing first-in-man applications.
In conclusion, our data demonstrate the role for canonical mTOR inhibitors used in DES in inducing EBD and that this dysfunction may be the driver of neoatherosclerosis. The off-target effect of these agents on displacing FKBP12.6 from RyR2 and inducing Ca 2+ -dependent activation of PKCα and disruption of the p120-VE-CAD interaction in the endothelium can be overcome by use of direct mTOR inhibitors. A role for newer mTOR inhibitors, such as ATP-competitive mTOR inhibitor used here, as therapeutic options for local elution in DES should be considered.
